碳离子放疗作为早期乳腺癌非手术治疗:II期试验5年结果
这项单中心前瞻性I/II期试验评估碳离子放疗(C-ion RT)用于≥60岁、I期、ER阳性、HER2阴性、肿瘤≤2 cm的浸润性导管癌患者,方案为60 Gy(RBE)分4次,并辅以内分泌治疗。II期部分12例患者5年局部控制率和无病生存率均为92%,总生存率100%,完全缓解率100%,毒性轻微且美容效果良好。
要点
- 5年局部控制率和无病生存率均为92%,总生存率100%。
- 完全缓解率100%,中位达完全缓解时间12个月(范围4-36个月)。
- 无≥2级急性不良事件,晚期仅1级肋骨骨折和乳腺炎相关疼痛。
核心结论
- 碳离子放疗在选择的早期乳腺癌患者中显示出优异的长期肿瘤控制、轻微毒性和良好美容效果,支持其作为医学上无法手术或拒绝手术患者的非手术替代方案。
研究设计与样本
- 单中心、前瞻性I/II期试验,II期部分纳入12例≥60岁、I期(cT1N0M0)、ER阳性、HER2阴性、肿瘤≤2 cm的浸润性导管癌女性患者。
主要发现
- 完全缓解率100%,中位达完全缓解时间12个月(范围4-36个月)。
- 5年局部控制率和无病生存率均为92%,总生存率100%。
- 1例高Ki-67指数患者出现野内复发。
- 急性1级皮炎6例,无≥2级急性不良事件;晚期1级肋骨骨折2例、1级乳腺炎相关疼痛3例,均保守处理。
- MRI显示7例亚临床胸肌炎症;除1例因复发行乳腺切除术外,所有患者维持优良美容效果。
关键数值与推荐
- 碳离子放疗总剂量60 Gy(RBE),分4次照射,后接辅助芳香化酶抑制剂。
- 主要终点为5年局部控制率,中位随访73个月。
临床怎么用
- 对于医学上无法手术或拒绝手术的早期乳腺癌患者,碳离子放疗可作为潜在的非手术选择。
- 治疗期间需关注急性皮炎和晚期肋骨骨折、乳腺炎相关疼痛等毒性,并保守处理。
- 需通过影像学评估肿瘤反应和亚临床胸肌炎症。
局限性
- II期部分样本量小(12例),需更大规模对照试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the long-term efficacy, safety, and cosmetic outcomes of carbon-ion radiation therapy (C-ion RT) as a nonsurgical treatment option for patients with early-stage breast cancer. METHODS AND MATERIALS: This single-center, prospective phase 1/2 trial enrolled women aged ≥60 years with stage I (cT1N0M0), estrogen receptor-positive, human epidermal growth factor receptor type 2-negative invasive ductal carcinoma, ≤2 cm in diameter. Patients received C-ion RT at a total dose of 60 Gy (relative biological effectiveness) in 4 fractions, followed by adjuvant aromatase inhibitors. The primary endpoint was 5-year local control. Secondary endpoints included complete response (CR) rate, adverse events (AEs), cosmetic outcomes, disease-free survival, and overall survival. Imaging was used for evaluating tumor response, and follow-up was conducted for a median of 73 months. RESULTS: Twelve patients were treated in the phase 2 component of the trial. The CR rate was 100%, with a median time to CR of 12 months (range, 4-36 months). The 5-year local control and disease-free survival rates were both 92%, and the overall survival rate was 100%. One case of in-field recurrence occurred in a patient with a high Ki-67 index. Acute grade 1 dermatitis was observed in 6 patients. No grade ≥2 acute AEs were reported. Regarding late AEs, grade 1 rib fractures (n = 2) and grade 1 mastitis-related pain (n = 3) were managed conservatively. Magnetic resonance imaging revealed subclinical pectoral muscle inflammation in 7 cases. All patients except one (who underwent mastectomy due to recurrence) maintained excellent cosmetic outcomes. CONCLUSIONS: C-ion RT demonstrated excellent long-term tumor control with minimal toxicity and favorable cosmetic outcomes in selected patients with early-stage breast cancer. These findings support its potential as a nonsurgical alternative for patients who are medically inoperable or decline surgery, warranting further investigation in larger, controlled trials.
引用
- Okonogi N, Karasawa K, Murata K, et al. Carbon-Ion Radiation Therapy as Nonsurgical Treatment for Early-Stage Breast Cancer: 5-Year Results From the Phase 2 Part of the First Prospective Clinical Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 42108880. doi:10.1016/j.ijrobp.2025.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。